Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) has announced that it will be reporting its first quarter financial results on Wednesday, May 8, 2024, after the close of the U.S. financial markets. The management team of Acadia will also be hosting a conference call and webcast on the same day at 4:30 p.m. Eastern Time to discuss the financial results and operations.
The conference call will be available on Acadia’s website, Acadia.com, under the investors section and will be archived there until June 7, 2024. Participants can also register for the call to receive an email with the dial-in number and unique PIN number to access the call.
Acadia Pharmaceuticals is a company that is dedicated to advancing breakthroughs in neuroscience to improve the quality of life. With 30 years of experience in the healthcare industry, Acadia has developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis, as well as the first and only FDA-approved drug for the treatment of Rett syndrome. The company’s clinical-stage development efforts are focused on various programs targeting neuropsychiatric symptoms in central nervous system disorders.
For more information about Acadia Pharmaceuticals, visit their website at Acadia.com and follow them on LinkedIn and Twitter. Investors can contact Al Kildani at (858) 261-2872 or ir@acadia-pharm.com, and Jessica Tieszen at (858) 261-2950 or ir@acadia-pharm.com for more information.